EFFECTIVENESS OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE IN PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ASSESSED BY ELECTRONEUROMYOGRAPHY OF SUPERFICIAL PERONEAL AND SURAL NERVES
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-4.19030Keywords:
acetylcholinesterase inhibitors, alpha-lipoic acid, chemotherapy, electroneuromyography, neuropathy, PaclitaxelAbstract
Aim: To investigate the neurofunctional parameters in breast cancer (BC) patients with paclitaxel-induced peripheral neuropathy (PIPN) and to clarify the feasibility of using alpha-lipoic acid (ALA) in combination with the acetylcholinesterase inhibitor ipidacrine hydrochloride (IPD) for its prevention. Materials and Methods: 100 BC patients (T1-4N0-3M0-1) prescribed for polychemotherapy (PCT) by the AT (paclitaxel, doxorubicin) or ET (paclitaxel, epirubicin) regimens in the neoadjuvant, adjuvant or palliative modes, were enrolled. The patients were randomized into two groups (n = 50 per group): group I treated by PCT only; group II treated with PCT plus the studied PIPN prevention scheme (ALA in combination with IPD). An electroneuromyography (ENMG) of the sensory (superficial peroneal and sural) nerves was performed before PCT, and after the 3 and 6 PCT cycles. Results: According to ENMG data, the electrophysiological disturbances in the sensory nerves were manifested in the form of axonal sensory peripheral neuropathy of a symmetrical nature, which was reflected in a decrease in the amplitude of the action potential (AP) of the studied nerves. The AP reduction in sensory nerves was dominant, in contrast to the nerve conduction velocity, which in most patients remained within the reference values, thus evidencing on axonal degeneration rather than demyelination as an underlying cause of PIPN. The ENMG testing of the sensory nerve in the groups of BC patients treated by PCT with paclitaxel with or without PIPN prevention treatment established that the use of ALA in combination with IPD significantly improved AP amplitude, duration and area of the response to the stimulation of the superficial peroneal and sural nerves after 3 and 6 PCT cycles. Conclusion: The use of ALA in combination with IPD significantly reduced the severity of damage to the superficial peroneal and sural nerves caused by PCT with paclitaxel and could be recommended for PIPN prevention.
References
Kudlowitz D, Muggia F. Defining risks of taxane neuropathy: insights from randomized clinical trials. Clin Cancer Res 2013; 19: 4570–7. doi: https://doi.org/10.1158/1078-0432.CCR-13-0572
Park SB, Kwok JB, Loy CT, et al. Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer 2014; 14: 993. doi: https://doi.org/10.1186/1471-2407-14-993
Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014; 155: 2461–70.
Scripture CD, Figg WD, Sparreboom A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol 2006; 4: 165–72. doi:10.2174/157015906776359568
Tanabe Y, Hashimoto K, Shimizu C, et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 2013; 18: 132–8. doi: https://doi.org/10.1007/s10147-011-0352-x
Staff NP, Grisold A, Grisold W, et al. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 2017; 81: 772–81. doi: https://doi.org/10.1002/ana.24951
Colvin LA. Chemotherapy-induced peripheral neuropathy: where are we now? Pain 2019; 160: 1–10. doi: https://doi.org/10.1097/j.pain.0000000000001540
Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 2020; 38: 3325–48. doi: https://doi.org/10.1200/jco.20.01399
Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 1941-67. doi: https://doi.org/10.1200/JCO.2013.54.0914
Bachegowda LS, Makower DF, Sparano JA. Taxanes: impact on breast cancer therapy. Anticancer Drugs 2014; 25: 512–21. doi: https://doi.org/10.1097/CAD.0000000000000090
Dyck PJ, Karnes JL, Daube J, et al. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Brain 1985; 108: 861–80. doi: https://doi.org/10.1093/brain/108.4.861
Esper GJ, Nardin RA, Benatar M, et al. Sural and radial sensory responses in healthy adults: diagnostic implications for polyneuropathy. Muscle Nerve 2005; 31: 628–32. doi: https://doi.org/10.1002/mus.20313
Rivner MH, Swift TR, Malik K. Influence of age and height on nerve conduction. Muscle Nerve 2001; 24: 1134–41. doi: https://doi.org/10.1002/mus.1124
LoMonaco M, Milone M, Batocchi AP, et al. Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 1992; 239: 199–204. doi: https://doi.org/10.1007/BF00839140
Chaudhry V, Rowinsky EK, Sartorius SE, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994; 35: 304–11. doi: https://doi.org/10.1002/ana.410350310
Pietrangeli A, Leandri M, Terzoli E, et al. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 2006; 56: 13–6.
Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004; 29: 387–92.
Argyriou AA, Kyritsis AP, Makatsoris T, et al. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 2014; 6: 135–47. doi:10.2147/CMAR.S44261
Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013; 63: 419–37. doi:10.3322/caac.21204
Fehrenbacher JC. Chemotherapy-induced peripheral neuropathy. Prog Mol Biol Transl Sci 2015; 131: 471–508. doi: https://doi.org/10.1016/bs.pmbts.2014.12.002
Holotiuk IS, Kryzhanivska AY, Holotiuk SI, et al. Evaluation of the efficiency of alpha-lipoic acid and ipidacrine hydrochloride for the prevention of paclitaxel-induced peripheral neuropathy according to the Total Neuropathy Score. Exp Oncol 2022; 44: 75–82. doi: 10.32471/exp-oncology.2312-8852.vol-44-no-1.17257
Berger T, Malayeri R, Doppelbauer A, et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 1997; 33: 1393–9.
Gornstein E, Schwarz TL. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology 2014; 76: 175–83.
Cavaletti G, Tredici G, Braga M, et al. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 1995; 133: 64-72. doi: https://doi.org/10.1006/exnr.1995.1008
Cavaletti G, Cavalletti E, Montaguti P, et al. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 1997; 18: 137–45.
Peters CM, Jimenez-Andrade JM, Kuskowski MA, et al. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007; 1168: 46–59. doi: https://doi.org/10.1016/j.brainres.2007.06.066
Imai S, Koyanagi M, Azimi Z, et al. Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. Sci Rep 2017; 7: 5947. doi: https://doi.org/10.1038/s41598-017-05784-1
Masurovsky EB, Peterson ER, Crain SM, et al. Morphological alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to taxol. Neuroscience 1983; 10: 491–509. doi: https://doi.org/10.1016/0306-4522(83)90148-3
Molè-Bajer J, Bajer AS. Action of taxol on mitosis: modification of microtubule arrangements and function of the mitotic spindle in Haemanthus endosperm. J Cell Biol 1983; 96: 527-40. doi: https://doi.org/10.1083/jcb.96.2.527
De Brabander M, Geuens G, Nuydens R, et al. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci USA 1981; 78: 5608–12. doi: https://doi.org/10.1073/pnas.78.9.5608
Letourneau PC, Ressler AH. Inhibition of neurite initiation and growth by taxol. J Cell Biol 1984; 98: 1355–62. doi: https://doi.org/10.1083/jcb.98.4.1355
Letourneau PC, Shattuck TA, Ressler AH. Branching of sensory and sympathetic neurites in vitro is inhibited by treatment with taxol. J Neurosci 1986; 6: 1912–7. doi: https://doi.org/10.1523/JNEUROSCI.06-07-01912.1986
Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39: 368–73. doi: https://doi.org/10.1212/wnl.39.3.368
Röyttä M, Horwitz SB, Raine CS. Taxol-induced neuropathy: short-term effects of local injection. J Neurocytol 1984; 13: 685–701. doi: https://doi.org/10.1007/BF01148489
Röytta M, Raine CS. Taxol-induced neuropathy: further ultrastructural studies of nerve fibre changes in situ. J Neurocytol 1985; 14: 157–75. doi: https://doi.org/10.1007/BF01150269
Röyttä M, Raine CS. Taxol-induced neuropathy: chronic effects of local injection. J Neurocytol 1986; 15: 483–96. doi: https://doi.org/10.1007/BF01611731
Gedlicka C, Kornek GV, Schmid K, et al. Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol 2003; 14: 339–40. doi: https://doi.org/10.1093/annonc/mdg051
Melli G, Taiana M, Camozzi F, et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol 2008; 214: 276–84. doi: https://doi.org/10.1016/j.expneurol.2008.08.013
Schloss J, Colosimo M, Vitetta L. New insights into potential prevention and management options for chemotherapy-induced peripheral neuropathy. Asia Pac J Oncol Nurs 2016; 3: 73–85. doi: 10.4103/2347-5625.170977
Kyte SL, Toma W, Bagdas D, et al. Nicotine prevents and reverses paclitaxel-induced mechanical allodynia in a mouse model of CIPN. J Pharmacol Exp Ther 2018; 364: 110–9. doi: https://doi.org/10.1124/jpet.117.243972
Toma W, Kyte SL, Bagdas D, et al. The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. Exp Neurol 2019; 320: 113010. doi: https://doi.org/10.1016/j.expneurol.2019.113010
Ishii N, Tsubouchi H, Miura A, et al. Ghrelin alleviates paclitaxel-induced peripheral neuropathy by reducing oxidative stress and enhancing mitochondrial anti-oxidant functions in mice. Eur J Pharmacol 2018; 819: 35–42. doi: https://doi.org/10.1016/j.ejphar.2017.11.024
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
